beta-alanine has been researched along with Arterial Obstructive Diseases in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This article reports an acute ischemic stroke after cardioversion and atrial flutter catheter ablation in a patient on treatment by dabigatran 110mg twice daily." | 7.79 | [Ischemic stroke after cardioversion and atrial flutter ablation in a patient taking dabigatran]. ( Amara, W; Guedeney, P; Iusuf, A, 2013) |
| "This article reports an acute ischemic stroke after cardioversion and atrial flutter catheter ablation in a patient on treatment by dabigatran 110mg twice daily." | 3.79 | [Ischemic stroke after cardioversion and atrial flutter ablation in a patient taking dabigatran]. ( Amara, W; Guedeney, P; Iusuf, A, 2013) |
| "Dabigatran is a reversible, direct thrombin inhibitor, which is administered as dabigatran etexilate, the oral prodrug." | 2.48 | New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. ( Dahl, OE, 2012) |
| "Dabigatran was stopped and dalteparin 5000 International Units/bid and 40 μg alprostadil infusions were started." | 1.38 | Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. ( Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amara, W | 1 |
| Guedeney, P | 1 |
| Iusuf, A | 1 |
| Sheffield, WP | 1 |
| Lambourne, MD | 1 |
| Eltringham-Smith, LJ | 1 |
| Bhakta, V | 1 |
| Arnold, DM | 1 |
| Crowther, MA | 1 |
| Dahl, OE | 1 |
| Stöllberger, C | 1 |
| Reiter, M | 1 |
| Schäffl-Doweik, L | 1 |
| Finsterer, J | 1 |
1 review available for beta-alanine and Arterial Obstructive Diseases
| Article | Year |
|---|---|
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Benzimidazoles; beta-Alan | 2012 |
3 other studies available for beta-alanine and Arterial Obstructive Diseases
| Article | Year |
|---|---|
[Ischemic stroke after cardioversion and atrial flutter ablation in a patient taking dabigatran].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Atrial Flutter; Benzimidazoles; beta-Alanine; Cat | 2013 |
γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Topics: Animals; Anticoagulants; Arterial Occlusive Diseases; Benzimidazoles; beta-Alanine; Bleeding Time; B | 2014 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazole | 2012 |